Abstract

Two simple, rapid, green non extractive spectrophotometric methods are described for the estimation of valsartan in tablet dosage form. The determination is based on the ion-pair formation using the dyes, bromophenol blue (BPB) and methyl red (MR). Valsartan forms ion-pair complex selectively with the dyes, as indicated by the formation of a coloured complex with BPB at pH 5.5 with λmax at 424 nm and MR at pH 4.3 with λmax at 494 nm. For both methods, optimal spectrophotometric conditions were established. The linear relationship was found between absorbance at λmax and concentration of drug in the range 8–24 µg/mL for BPB and 4–20 µg/mL for MR. Regression analysis of Beer’s law plot at 424 nm yielded the regression equation, y = 0.0102x + 01636 (BPB) and at 494 nm y = 0.0222x – 0.0063 (MR). High values of correlations coefficient (R2 = 0.9988 (BPB) and R2 = 0.9991 (MR)) and small values of intercept validated the linearity of calibration curve and obedience to Beer’s law. The LOD and LOQ values were calculated to be 1.03 µg/mL and 3.43 µg/mL respectively (BPB) and 0.68 µg/mL and 2.26 µg/mL respectively (MR). Intra-day and inter-day accuracy and precision, robustness were in acceptable limits. The proposed methods were applied for the quantification of valsartan in tablets pertaining to three commercial formulations. Analytical eco-scale for greenness assessment of the proposed spectrophotometric methods showed that both methods corresponds to excellent green analysis with a score of 89.

Highlights

  • Valsartan is an antihypertensive drug, a specific angiotensin II receptor antagonist

  • We aimed to develop and validate rapid, simple and green non extractive spectrophotometric methods for the determination of valsartan in tablet dosage form

  • Maximal absorbance was observed in methanol solution with bromophenol blue (BPB) and ethanol solution with methyl red (MR) and while chloroform, propanol, acetonitrile and ethylacetate were not suitable

Read more

Summary

Introduction

Valsartan is an antihypertensive drug, a specific angiotensin II receptor antagonist. Valsartan acts selectively on AT1 subtype receptors. It is prescribed for hypertension, post-infarction, for the treatment of symptomatic heart failure, when it is impossible to use ACE inhibitors or as adjunctive therapy with ACE inhibitors, when it is impossible to use β-blockers. Valsartan is (2S) -3-methyl-2- [pentanoyl [[2`- (1H-tetrazol-5-yl) biphenyl-4-yl] methyl] amino] butanoic acid (Figure 1) (Ph. Eur 2020).

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call